ESMO 2022 | EMERALD-3: tremelimumab + durvalumab with or without lenvatinib combined with TACE in HCC

Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, provides an overview of the rationale and study design of the EMERALD-3 trial (NCT05301842), a randomised Phase III study of tremelimumab plus durvalumab with or without lenvatinib combined with concurrent transarterial chemoembolisation (TACE) versus TACE alone in patients with locoregional hepatocellular carcinoma (HCC). Dr Abou-Alfa also discusses the limitations of sorafenib and emphasises the importance of ensuring widespread access to new effective therapies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.